Abstract 3749: The evaluation of expression level of Cxcl12 gene in peripheral blood samples of breast cancer patients

Abstract

Abstract Breast cancer, like many other cancer types, is linked to the activation and overexpression of CXCR4. The overexpression of CXCR4 is associated with factors such as tumor growth, angiogenesis, increased metastasis, and therapeutic resistance. Similarly, CXCL12, a specific ligand for CXCR4, plays a significant role in tumorigenesis processes, including survival, migration, and microenvironmental interactions. The CXCL12/CXCR4 signaling pathway has been found to impact the development and progression of breast cancer, regulating proliferation, motility, and metastasis. Hence, molecules within the CXCL12/CXCR4 signaling pathway hold promise for determining breast cancer prognosis, treatment monitoring, and serving as therapeutic agents. The study, conducted at the Istanbul University Institute of Oncology, obtained ethical approval from the Istanbul Faculty of Medicine Ethics Committee. Genetic materials from 300 breast cancer patients and 150 control subjects underwent standard testing, matched based on crucial parameters. Real-time PCR with the MIC qPCR Cycler was statistically analyzed using GraphPad Prism (p < 0.05). Descriptive statistics were presented for categorical and quantitative variables, while the Kolmogorov-Smirnov test assessed the normal distribution of quantitative variables. Statistical comparisons between groups were performed using the Mann-Whitney U test and the Kruskal-Wallis test. was used for calculations. Notably, among the three genes—LASP1, CXCL12, and CXCR4—LASP1 exhibited the highest mean expression level at 11.64 with a considerable standard deviation of 11.80. In contrast, CXCL12 had a much lower mean expression level at 2.96 and a tighter distribution, and CXCR4 displayed the lowest mean expression level at 0.37 with a standard deviation of 0.74. The analysis of diagnostic groups indicated no significant differences in mean LASP1 and CXCL12 levels, but a significant variance in mean CXCR4 levels (p<0.001). Specifically, CXCR4 expression in group Breast and ovarian cancer was notably lower compared to Breast cancer, Bilateral Breast cancer, and Breast and Other cancer, while group Breast cancer exhibited significantly lower CXCR4 expression compared to groups Bilateral Breast cancer and Breast and Other cancer. However, there was no significant difference in CXCR4 expression between groups of Bilateral Breast cancer and Breast and Other cancer. These findings reveal distinct expression patterns of CXCR4 across diagnostic groups, suggesting potential implications for diagnostic categorization and underlying molecular pathways in breast cancer. Understanding these expression disparities could be crucial in deciphering the molecular intricacies influencing disease progression and treatment responses. Citation Format: Arash Adamnejad Ghafour, Seref Bugra Tuncer. The evaluation of expression level of Cxcl12 gene in peripheral blood samples of breast cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3749.